Property | Value |
?:abstract
|
-
T cells in the immune system protect the human body from infection by pathogens and clear mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy, by relying on this basic recognition method, boosts the antitumor efficacy of T cells by unleashing the inhibition of immune checkpoints and expands adaptive immunity by facilitating the adoptive transfer of genetically engineered T cells. T cells genetically equipped with chimeric antigen receptors (CARs) or TCRs have shown remarkable effectiveness in treating some hematological malignancies, although the efficacy of engineered T cells in treating solid tumors is far from satisfactory. In this review, we summarize the development of genetically engineered T cells, outline the most recent studies investigating genetically engineered T cells for cancer immunotherapy, and discuss strategies for improving the performance of these T cells in fighting cancers.
|
is
?:annotates
of
|
|
?:creator
|
|
?:doi
|
-
10.1038/s41392-019-0070-9
|
?:doi
|
|
?:externalLink
|
|
?:journal
|
-
Signal_Transduct_Target_Ther
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/663eda55622d5106c79727187327cf8b0a1e653e.json
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC6799837.xml.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
Genetically engineered T cells for cancer immunotherapy
|
?:type
|
|
?:year
|
|